Gabapentin Tablet, Film Coated
Product Images NDC 16714-332

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 16714-332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Gabapentin Fig1)

This appears to be a formula for calculating Lt (likely meaning "renal function" or "glomerular filtration rate") based on a person's age and weight multiplied by their creatinine measurement. The creatinine measurement given is specific to female patients. However, without additional context it is impossible to determine the purpose or significance of this formula.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

The text provides a figure and a graph displaying the mean pain scores observed cases in ITT Population for Study 1 during the 4Week Dose Tiation Perod and 4Week Fixed Duse Period. The graph compares the placebo and gabapentin 3600 mg/day group. There is no further information available to provide additional context.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

The text describes a graph of weekly mean pain scores in a study. The study had a 10 to 3-week dose titration period and a 4-week fixed dose period. The graph shows the observed cases in the ITT population. The graph includes a placebo, gabapentin (1800 mg/day) and gabapentin (2400 mg/day). The graph displays the mean pain score at baseline and weeks 1 to 7.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

The text describes a chart showing the proportion of responders in controlled PHN studies. The chart shows the percentage of patients who experienced a reduction in pain score of 250% at the end of the study. The chart has two labeled studies (Study 1 and Study 2) with a corresponding percentage of responders. There are also labels for PBO, GBP1800, GBP200, PBO 6BP, and 3600.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

This appears to be a figure with a graph showing the responder rate of patients receiving Gabapentin as an Adjunctive Therapy in the treatment of Partial Seizures. The graph shows the difference in responder rate between Gabapentin and Placebo for different doses of Gabapentin ranging from 600mg to 1800mg daily dose. Therefore, there is no useful description to give.*

FDA Label Image

Package Label-principal Display Panel – 600 mg (100 Tablets Bottle) (Gabapentin Fig6)

FDA Label Image

Package Label-principal Display Panel – 800 mg (100 Tablets Bottle) (Gabapentin Fig7)

This is a description for a medication called Gabapentin, manufactured by Aurobindo Pharma Limited. Each film-coated tablet contains 800mg of Gabapentin and the recommended dosage is available in the package insert. Northstar Rx LLC is the company that the medication was manufactured for and the product can be obtained through their website or by phone. There are 100 tablets in the package and the medication should be stored at 20 to 25 degrees Celsius. The instruction also recommends that the pharmacist dispense the medication guide provided separately to each patient.*

FDA Label Image

Chemical Structure (Gabapentin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.